Harold Simmons Center for Chronic Disease Research & Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90509-2910, USA.
Am J Kidney Dis. 2012 Jun;59(6):841-8. doi: 10.1053/j.ajkd.2011.12.014. Epub 2012 Feb 4.
Recent studies show a survival advantage with kidney transplant in elderly patients compared with those on dialysis therapy.
In our present study, we examined and compared the association of expanded criteria donor (ECD) kidney and living kidney donation with the outcome of kidney transplant across different ages, including elderly recipients.
SETTING & PARTICIPANTS: Using the Scientific Registry of Transplant Recipients, we identified 145,470 adult kidney transplant patients. Mortality and death-censored transplant failure risks were estimated by Cox proportional regression analyses during follow-up with a median of 3.9 years.
ECD kidney and living kidney donation and age compared with others.
Mortality and death-censored transplant failure risk.
Patients were aged 45 ± 16 years and included 40% women and 19% patients with diabetes. Compared with transplant recipients 55 to younger than 65 years, the fully adjusted death-censored transplant failure risk was higher in patients 75 years and older (HR, 1.30; 95% CI, 1.09-1.56), 35 to younger than 55 years (HR, 1.13; 95% CI, 1.08-1.17), and 18 to younger than 35 years (HR, 1.64; 95% CI, 1.57-1.71). Compared with non-ECD kidneys, ECD kidneys were significant predictors of mortality in nonelderly patients (18-<35 years: HR, 1.46 [95% CI, 1.19-1.77]; 35-<55 years: HR, 1.23 [95% CI, 1.14-1.32]; and 55-<65 years: HR, 1.26 [95% CI, 1.15-1.38]) and patients 65 to younger than 70 years (HR, 1.20; 95% CI, 1.05-1.36), but not in other groups of elderly patients (HRs of 1.12 [95% CI, 0.93-1.36] for 70-<75 years and 1.04 [95% CI, 0.74-1.47] for ≥75 years). Similar results were found for risk of transplant loss. Compared with deceased donor kidneys, a living donor kidney was associated with better survival in all age groups and lower transplant loss risk in patients younger than 70 years.
Unmeasured confounders cannot be adjusted for.
For deceased donors, ECD kidneys are not associated with increased mortality or transplant failure in recipients older than 70 years. For all types of donors, the persistent association between living donor kidneys and lower all-cause mortality across all ages suggests that, if possible, elderly patients gain longevity from living donor kidney transplant.
最近的研究表明,与透析治疗相比,老年患者接受肾移植的生存率更高。
在我们目前的研究中,我们检查并比较了扩展标准供体(ECD)肾脏和活体肾脏捐献与不同年龄的肾移植结果之间的关联,包括老年受者。
使用 Scientific Registry of Transplant Recipients,我们确定了 145470 名成年肾移植患者。通过 Cox 比例风险回归分析在中位 3.9 年的随访期间估计死亡率和死亡校正的移植失败风险。
ECD 肾脏和活体肾脏捐献以及年龄与其他因素相比。
死亡率和死亡校正的移植失败风险。
患者年龄为 45±16 岁,包括 40%的女性和 19%的糖尿病患者。与 55 岁至 65 岁以下的移植受者相比,75 岁及以上的患者(HR,1.30;95%CI,1.09-1.56)、35 岁至 55 岁以下(HR,1.13;95%CI,1.08-1.17)和 18 岁至 35 岁以下(HR,1.64;95%CI,1.57-1.71)的死亡校正移植失败风险更高。与非 ECD 肾脏相比,ECD 肾脏是非老年患者(18-<35 岁:HR,1.46[95%CI,1.19-1.77];35-<55 岁:HR,1.23[95%CI,1.14-1.32];和 55-<65 岁:HR,1.26[95%CI,1.15-1.38])和 65 岁至 70 岁以下的患者(HR,1.20;95%CI,1.05-1.36)的死亡率和移植失败的独立预测因素,但在其他老年患者组中并非如此(HR 为 1.12[95%CI,0.93-1.36]为 70-<75 岁,HR 为 1.04[95%CI,0.74-1.47]为≥75 岁)。在移植丢失风险方面也发现了类似的结果。与已故供体肾脏相比,活体供体肾脏与所有年龄组的生存率提高和 70 岁以下患者的移植失败风险降低相关。
无法调整未测量的混杂因素。
对于已故供体,ECD 肾脏与 70 岁以上患者的死亡率或移植失败增加无关。对于所有类型的供体,活体供体肾脏与所有年龄段的全因死亡率持续降低之间的关联表明,如果可能的话,老年患者从活体供体肾移植中获得长寿。